SOURCE: Huifeng Bio-Pharmaceutical Technology, Inc.

July 12, 2007 12:02 ET

Huifeng Bio-Pharmaceutical Announces Supply Agreement With Safic-Alcan Espana S.A.

XI'AN, CHINA--(Marketwire - July 12, 2007) - Huifeng Bio-Pharmaceutical Technology, Inc. (OTCBB: HFGB), a rapidly growing Chinese company which produces raw materials for pharmaceutical and nutraceutical production, announced on July 4, 2007, a ten-year agreement with French Safic-Alcan's subsidiary, Safic-Alcan Espana S.A., to supply Troxerutin in Spain.

Troxerutin is a derivative of the natural bioflavonoid Rutin, which is extracted from Sophora japonica. Troxerutin is best suited for the treatment of pre-varicose vein syndrome, varicose ulcers, trombophlebitis, post-phlebitic conditions, chronic venous deficiency, and hemorrhoids. Troxerutin can also be successfully applied for muscle pain and edemas due to traumatic vein blood-flow disorders and hematomes.

"We are very pleased with this agreement that launches a new relationship between Huifeng and Safic-Alcan Espana S.A.," said Jing'An Wang, CEO of Huifeng Bio-Pharmaceutical Inc. "This agreement will be of significant benefit to both Huifeng and Safic-Alcan customers. We believe this agreement strengthens the distribution channel for Huifeng and opens new doors for the Company's ever expanding pharmaceutical and nutraceutical market."

Safic-Alcan Espana S.A., headquartered in Barcelona, Spain, is one of seven subsidiaries of Safic-Alcan. Safic-Alcan and its subsidiaries distributes, prepares and commercializes specialty chemicals for formulating industries such as rubber, thermoplastics, cosmetics, pharmaceuticals and food. Safic-Alcan has long lasting relationships with DuPont and Dow Chemical that reach from France to Spain and Portugal as well as into the Scandinavian countries.

About Huifeng Bio-Pharmaceutical Technology, Inc.

Huifeng Bio-Pharmaceutical Technology, Inc. located in Xi'an, People's Republic of China, develops and produces plant extracts and pharmaceutical raw materials for use in pharmaceutical, nutraceutical and food production. It is the leading Chinese producer of rutin and related, plant-derived chemicals in a class called flavonoids, with medicinal and other beneficial properties. Founded in 2002, Huifeng uses proprietary patented processes to extract rutin more efficiently than traditional extraction techniques. The Company is diversifying its product lines through internal development, acquisition and cooperation with scientific research organizations.

Forward-Looking statements

This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, and other risks defined in this document and in statements filed from time to time with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the companies, are expressly qualified by the cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the companies disclaim any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.

Contact Information